Compare Invesco DB Agriculture Fund (DBA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Novo Nordisk A/S — how do they compare? Invesco DB Agriculture Fund trades at $28.53 (market cap $1.32B), while Novo Nordisk A/S trades at $38.12 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 125.2× Invesco DB Agriculture Fund's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Novo Nordisk A/S for 116 Days on average.
| DBA | NVO | |
|---|---|---|
Market Cap | $1.32B | $165.31B |
Volume | 771,657 | 11,432,838 |
52-Week High | $29.49 | $63.98 |
52-Week Low | $25.44 | $35.29 |
Typical Hold Time | 24 Days | 116 Days |
Sector | — | Health |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong year-to-date performance with 12.4% returns matching the S&P 500. The technical outlook remains bullish with moving averages signaling strength and ADX indicators confirming trend momentum. Recent news highlights agricultural ETF outperformance driven by weather risks, geopolitical tensions, and strong global demand for commodities.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and climate factors, though the 0.85% expense ratio and commodity volatility present risks. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish technical consolidation near all-time highs since 2020.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
